Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 02.08.2021 16:25
Latest

7.82 NOK

Change

-0.06

Change (%)

-0.76

HBC 1
LATEST REPORT

Annual Report

Download our latest report, or view all quarterly and yearly reports in the archives.

16:9
NEXT UP

Financial calendar

Half-yearly Report
27.08.2021

Quarterly Report Q3
05.11.2021

Quarterly Report Q4
04.02.2022

Investor presentation

Download our latest investor presentation in PDF-format for a even deeper insight into our current ongoing business and future potential.

Download presentation

Contact investor relations

James Berger
James Berger
Chief Commercial Officer
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Head of Medical R&D
+44 7968 195497 cc@hofsethbiocare.no